These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15086907)

  • 1. Effect of the calcimimetic NPS R-467 on furosemide-induced nephrocalcinosis in the young rat.
    Pattaragarn A; Fox J; Alon US
    Kidney Int; 2004 May; 65(5):1684-9. PubMed ID: 15086907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of age on furosemide-induced nephrocalcinosis in the rat.
    Osorio AV; Alon MM; Nichols MA; Alon US
    Biol Neonate; 1998; 73(5):306-12. PubMed ID: 9573460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism.
    Wada M; Nagano N; Furuya Y; Chin J; Nemeth EF; Fox J
    Kidney Int; 2000 Jan; 57(1):50-8. PubMed ID: 10620187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.
    Goodman WG; Frazao JM; Goodkin DA; Turner SA; Liu W; Coburn JW
    Kidney Int; 2000 Jul; 58(1):436-45. PubMed ID: 10886592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium.
    Fox J; Lowe SH; Petty BA; Nemeth EF
    J Pharmacol Exp Ther; 1999 Aug; 290(2):473-9. PubMed ID: 10411552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2+) receptor in rats.
    Fox J; Lowe SH; Conklin RL; Petty BA; Nemeth EF
    J Pharmacol Exp Ther; 1999 Aug; 290(2):480-6. PubMed ID: 10411553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of thiazide on established furosemide-induced nephrocalcinosis in the young rat.
    Knoll S; Alon US
    Pediatr Nephrol; 2000 Jan; 14(1):32-5. PubMed ID: 10654327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salt supplementation, growth, and nephrocalcinosis in the furosemide-treated weanling rat.
    Gratny LL; Ringer K; Hall RT; Alon US
    Biol Neonate; 1997; 71(1):37-45. PubMed ID: 8996656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histological long-term outcome of furosemide-induced nephrocalcinosis in the young rat.
    Alon US; Kaplan RA; Gratny LL; Nichols MA
    Pediatr Nephrol; 1996 Apr; 10(2):191-4. PubMed ID: 8703710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of NPS R-467 on PTH secretion of cultured parathyroid cells from secondary hyperparathyroidism patients].
    Wang X; Wang N; Hu J
    Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(21):1321-3. PubMed ID: 16200727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcimimetics normalize the phosphate-induced stimulation of PTH secretion in vivo and in vitro.
    Almaden Y; Rodriguez-Ortiz ME; Canalejo A; Cañadillas S; Canalejo R; Martin D; Aguilera-Tejero E; Rodríguez M
    J Nephrol; 2009; 22(2):281-8. PubMed ID: 19384847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.
    Mizobuchi M; Hatamura I; Ogata H; Saji F; Uda S; Shiizaki K; Sakaguchi T; Negi S; Kinugasa E; Koshikawa S; Akizawa T
    J Am Soc Nephrol; 2004 Oct; 15(10):2579-87. PubMed ID: 15466262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daily transient decreases in plasma parathyroid hormone levels induced by the calcimimetic NPS R-568 slows the rate of bone loss but does not increase bone mass in ovariectomized rats.
    Miller MA; Fox J
    Bone; 2000 Oct; 27(4):511-9. PubMed ID: 11033446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.
    Henley C; Yang Y; Davis J; Lu JY; Morony S; Fan W; Florio M; Sun B; Shatzen E; Pretorius JK; Richards WG; St Jean DJ; Fotsch C; Reagan JD
    J Pharmacol Exp Ther; 2011 Jun; 337(3):681-91. PubMed ID: 21422163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor.
    Wada M; Furuya Y; Sakiyama J; Kobayashi N; Miyata S; Ishii H; Nagano N
    J Clin Invest; 1997 Dec; 100(12):2977-83. PubMed ID: 9399943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism.
    Fox J; Lowe SH; Conklin RL; Nemeth EF
    Endocrine; 1999 Apr; 10(2):97-103. PubMed ID: 10451217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
    Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands.
    Rodriguez ME; Almaden Y; Cañadillas S; Canalejo A; Siendones E; Lopez I; Aguilera-Tejero E; Martin D; Rodriguez M
    Am J Physiol Renal Physiol; 2007 May; 292(5):F1390-5. PubMed ID: 17200160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological activity of calcimimetic NPS R-568 administered intravenously in rats: dose dependency.
    Rybczyńska A; Boblewski K; Lehmann A; Orlewska C; Foks H
    Pharmacol Rep; 2006; 58(4):533-9. PubMed ID: 16963800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.